Onconetix (NASDAQ:ONCO) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Onconetix (NASDAQ:ONCO – Free Report) from a sell rating to a hold rating in a report issued on Saturday.

Separately, Weiss Ratings downgraded Onconetix from a “sell (e+)” rating to a “sell (e)” rating in a research report on Tuesday, August 11th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

Get Onconetix alerts:

Read Our Latest Report on Onconetix

Onconetix Stock Down 6.6%

Shares of ONCO opened at $0.76 on Friday. The firm has a market cap of $863,550.00, a PE ratio of 0.00 and a beta of 2.69. The company’s fifty day moving average is $0.93 and its two-hundred day moving average is $15.66. Onconetix has a fifty-two week low of $0.67 and a fifty-two week high of $209.50.

Onconetix (NASDAQ:ONCO – Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The company reported ($1.28) EPS for the quarter, topping analysts’ consensus estimates of ($4,505.00) by $4,503.72. The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.02 million. Onconetix had a negative return on equity of 91.95% and a negative net margin of 1,575.89%.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Onconetix stock. Citadel Advisors LLC acquired a new position in shares of Onconetix, Inc. (NASDAQ:ONCO – Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 15,633 shares of the company’s stock, valued at approximately $49,000. Citadel Advisors LLC owned 1.00% of Onconetix as of its most recent SEC filing. 23.89% of the stock is owned by hedge funds and other institutional investors.

About Onconetix

(Get Free Report)

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc and changed its name to Onconetix, Inc in December 2023. Onconetix, Inc was incorporated in 2018 and is headquartered in Cincinnati, Ohio.

Read More

• Five stocks we like better than Onconetix
• Commodities Are Booming, But These 3 ETFs Tell Different Stories
• 3 Active ETFs Making Big Moves in August
• This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
• Birkenstock Beats the Skeptics—But Not on EPS

Receive News & Ratings for Onconetix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconetix and related companies with MarketBeat.com's FREE daily email newsletter.